PCN18 OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES- THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74270-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)74270-4/fulltext
Title :
PCN18 OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES- THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74270-4&doi=10.1016/S1098-3015(10)74270-4
First page :
Section Title :
Open access? :
No
Section Order :
196